综合护理干预对肺癌胸腔镜术后患者的影响

目的探讨对肺癌胸腔镜术后患者行综合护理干预对于并发症以及生存质量的临床影响。方法抽取到本院接受治疗的132例肺癌胸腔镜术后患者,研究时间为2017年1月—2018年12月,将其按照双盲法分成综合组和对照组,分别为66例患者。综合组行综合护理措施,对照组行常规护理措施,观察两组患者的临床资料,并且比较两组患者的并发症以及生存质量。结果综合组患者接受护理后并发症发生率3例(4.55%),明显低于对照组11例(16.67%),综合组生存质量评分均高于对照组,P<0.05。结论对肺癌胸腔镜术后患者行综合护理干预,降低并发症的发几率,提高了生存质量。     

止血凝胶封闭微创经皮肾通道的安全性及可行性研究

目的 研究止血凝胶封闭微创经皮肾通道的安全性及可行性.方法 采用MPCNL治疗的简单性肾结石及输尿管上段结石80例,对照组术后放置14 F肾造瘘管,实验组采用止血凝胶封闭微创经皮肾通道,不放置肾造瘘管,手术为单通道.统计学分析对照组与实验组术后患者疼痛需要应用镇痛药物的发病率和剂量、手术后患者血红蛋白下降情况、术后患者术后出现持续出血,感染及尿外渗等并发症发生情况以及手术后住院的时间.结果 两组患者均一期手术成功,对照组患者术后疼痛需要应用镇痛药物的发病率明显高于实验组(42.5％ vs 20％),而术后出现出血、感染等并发症的发病率以及手术后的住院时间,差异无统计学意义(P＞0.05).两组患者术后复查均未出现肾周围血肿,对照组患者出现7例拔出造瘘管后的漏尿.结论 止血凝胶封闭微创经皮肾通道的经皮肾碎石取石术降低了患者手术后的痛苦,避免手术后拔出肾造瘘管漏尿的发病率,对于简单的肾结石和输尿管结石患者是安全可靠的手术方式.     

超声技术在椎管内麻醉穿刺中的应用进展

超声作为一种可视化技术,在椎管内麻醉穿刺中的应用取得了很大进展。椎管内麻醉是下腹部和下肢手术的常用麻醉方法。超声能够清楚地显示椎管及其周围解剖结构,使椎管内麻醉走向精准化具有重大意义。用超声在椎管内麻醉穿刺前扫描,可预测穿刺的困难程度、定位穿刺点、测量穿刺深度,从而提高椎管内麻醉穿刺的成功率;实时超声引导下椎管内麻醉穿刺能实时地观察穿刺针的角度和深度,使麻醉穿刺全程可见;将超声应用于困难椎管内穿刺及小儿椎管内穿刺,可降低多次穿刺带来的并发症及风险,具有深远的意义。     

The evolving landscape of N6-methyladenosine modification in the tumor microenvironment

1. Download : Download high-res image (125KB)
2. Download : Download full-size image

     

HST-1流水线进行血液分析的复检措施分析及临床应用

目的探讨全自动血液分析仪检测血常规的临床复检方法及措施，统计分析血常规检测的复检原因。方法按临床标本的检测流程和方法对6084个门诊和住院标本进行全血细胞分析检测，按我室初步制定的复检规则确定复检标本，进行临床复检工作并完成统计学评估。结果6084例标本中3867例标本可以直接报告，无需复检，2217例标本需要复检（占总标本数的36．44％）。复检标本中观察标本一般性状的占187例（3．07％），需仪器复检的标本495例（8．14％），需显微镜观察评估细胞数量或形态105例（1．73％），需人工镜检分类计数的标本1430例（23．5％）。分析以上复检措施可见，观察标本一般性状复检的符合率为100％，仪器复检符合率为62．3％，显微镜观察评估细胞的符合率为73．1％，人工镜检分类计数的符合率为74．2％。结论制定临床适用的复检规则具有很重要的临床意义，严格而有技巧地执行该规则，可提高实验室的工作效率，为临床提供更准确优质的服务。     

急性冠状动脉综合征患者血清白细胞介素-10、18及肿瘤坏死因子α水平及其临床意义

目的:评价血清白细胞介素(IL)-18、肿瘤坏死因子α(TNF-α)和IL-10水平与急性冠状动脉综合征(ACS)的关系及其临床意义。方法:冠心病(CHD)患者91例,分为ACS组、稳定型心绞痛(SAP)组;非CHD患者55例作为对照组,采用ELISA法测定血清IL-18、TNF-α和IL-10浓度并分析。结果:CHD患者血清IL-18和TNF-α水平明显高于对照组(P<0.01),而血清IL-10明显低于对照组(P<0.01);与SAP组相比,ACS组血清IL-18和TNF-α水平明显升高(P<0.01),而血清IL-10水平则显著降低(P<0.01)。且随着冠状动脉狭窄程度的增加,IL-18的水平逐渐增高。结论:IL-18、TNF-α和IL-10可以反映动脉粥样硬化斑块的严重程度和稳定状态,可作为监测病情的临床生化指标。     

氟康唑注射液耳浴治疗真菌性外耳道炎71例

目的探讨氟康唑注射液耳浴治疗真菌性外耳道炎的方法和疗效。方法对真菌性外耳道炎患者139例,分成观察组71例和对照组68例,观察组用氟康唑注射液耳浴治疗,对照组用达克宁霜涂布治疗。随访1年。结果两种方法治疗真菌性外耳道炎均有效,但随访1年,达克宁组复发率比氟康唑组高,差异有统计学意义(P<0.05)。结论氟康唑注射液耳浴治疗真菌性外耳道炎复发率低,操作简便,患者依从性佳。     

疑似强直性脊柱炎患者HLA-B27检测与分析

目的通过对872例强直性脊柱炎(AS)疑似患者HLA-B27抗原的检测,分析HLA-B27抗原与AS的相关性及其临床意义。方法选取872例AS疑似患者外周血,采用流式细胞仪检测T淋巴细胞膜上的HLA-B27/B7抗原,并对患者的表达情况进行分析。结果 872例AS疑似患者男女比例为1.8∶1,HLA-B27抗原总阳性率为27.29%,,男女患者阳性率分别为32.50%和17.95%(P0.05),男女患者B27+/B7-单抗表达率(%)分别为39.16±42.79和20.96±33.86(P0.05),平均荧光强度分别为5.35±5.44和3.35±3.87(P0.05),差别显著。结论用流式细胞技术检测T淋巴细胞HLA-B27的有助于AS的诊断和鉴别诊断。     

A phase I study investigation of metabolism,and disposition of [ 14 C]-anlotinib after an oral administration in patients with advanced refractory solid tumors

Anlotinib is a novel oral multi-targeted receptor tyrosine kinase inhibitor, which selectively inhibits VEGFR2/3, FGFR1-4, PDGFR α/β, c-kit, and Ret. It shows antitumor effect in patients with advanced refractory solid tumors. The detailed absorption, metabolism, and excretion pathways of anlotinib have not yet been fully investigated. Six male patients were enrolled and divided into two groups. Group A (containing two patients) received 14.15 mg/80 µCi/subject [14C]-anlotinib hydrochloride. Group B (containing four patients) received 14.15 mg/120 µCi/subject [14C]-anlotinib hydrochloride. The blood, urine, and feces of all the six patients after orally administration of [14C]-anlotinib were collected. The absorption, metabolism, and excretion of [14C]-anlotinib were investigated, and the efficacy and safety of anlotinib were evaluated. In plasma, the average time to peak concentration (Tmax) of total radioactivity was 4.42 h and the average peak concentration (Cmax) of total radioactivity was 18.80 ng Eq./g. The average values of AUC0-last, AUC0-∞, and MRT0-t were 4071 h.ng Eq./g, 13,555 h.ng Eq./g, and 125 h, respectively. The average recovery of total radioactivity (TRA) in urine and feces was 62.03%, accounting for 48.52% and 13.51% in feces and urine of the total dosage, respectively. The parent drug, a carboxylic metabolite (M30), and mono-oxidation products (M46/M66) were major drug-related components in human plasma. Oxidative metabolism played the major role in drug clearance in human. The major metabolic pathways include oxidative deamination to M2, mono-oxidation to M1, and the formation of M30. Adverse events occurred in five patients and severe adverse events (SAE) occurred in one. Tumor response were evaluated as stable disease (SD) in three, partial response (PR) in one, and progressive disease (PD) in one of the patients, respectively. Anlotinib had a good pharmacokinetic profile with rapid absorption, long half-life, and extensive hepatic metabolism. The adverse events and efficacy were as expected.